Scandinavian Biopharma continues to grow – 2016 was another successful year
2016 was another successful year with continued strong growth for Scandinavian Biopharma. For the distribution business, which are conducted through the subsidiary Scandinavian Biopharma Distribution, revenue growth landed at impressive 43%. At a group level the growth was 7 % in 2016 as revenues increased from 44,2 million SEK in 2015 to 47,3 million SEK in 2016.
“We can look back on a fantastic year for our distribution business, the group’s growth engine, where revenue was increased from 31,3 million SEK 2015 to 44,7 million SEK 2016. At the same time our clinical development program has taken important steps forward,” says CEO Björn Sjöstrand.
In February 2017, the last patient was enrolled in a Phase I/II study in Bangladesh where the new ETEC vaccine was tested for safety and immunogenicity in different age groups down to 6 months young infants.
We have now started a phase IIB study in Finnish travellers, where safety, analytical methods and the vaccine’s protective effect will be evaluated.
“The studies in Bangladesh are essential steps toward showing that our vaccine can protect children in the developing world against ETEC diarrhoea, a disease that causes millions of diarrheal events and several hundred thousand of death’s every year. This year, we hope to show that the same vaccine is also effective for travellers suffering from a diarrhoea caused by ETEC”, says Björn Sjöstrand, CEO at Scandinavian Biopharma.
Scandinavian Biopharma business has demonstrated strong organic growth since the company was launched in late 2009 and has since 2013 gained profit.
For further information, please contact:
Björn Sjöstrand, CEO: +46 (0)727-125 120, Bjorn.sjostrand@scandinavianbiopharma.se
